Introduction
CATHAY (TAIYUAN) BIOMATERIAL CO., LTD. is the Taiyuan-based industrial platform associated with Cathay Biotech, a Chinese company focused on bio-based materials and synthetic-biology-enabled manufacturing for the plastics and polymer value chain. In the Chinaplas exhibitor database, the company is listed as a plastics and rubber supplier, reflecting its role in polymer-related upstream materials rather than in finished consumer products.
The broader Cathay Biotech group was founded in 2000 and is headquartered with its R&D center in Shanghai, while its manufacturing footprint includes sites in Jinxiang and Wusu, with a Taiyuan site under development to expand capacity for long-chain diacids, pentamethylene diamine (PDA), and bio-based polyamides. Its materials are positioned around the polyamide industry chain, serving applications that require performance plastics derived from renewable or bio-manufactured feedstocks.
History and Development
Cathay Biotech, the parent group of the Taiyuan biomaterials platform, was founded in 2000 and later became a STAR Market listed company on the Shanghai Stock Exchange in 2020. The company’s development has centered on building industrial-scale bio-manufacturing capabilities for polymer intermediates and polyamides.
Key milestones in the group’s development include:
- 2020: Listing on the Shanghai STAR Market, providing capital access for industrial expansion and R&D.
- 2021: The Wusu plant began production of bio-based PDA and PA5X polyamides, marking an important commercialization step.
- Taiyuan expansion: Public company statements and industry coverage identify Taiyuan as a major new production base intended to increase output of long-chain diacids, pentanediamine, and bio-based polyamides.
The Taiyuan company itself is publicly associated with the group’s expansion in Shanxi, including project activity in the Shanxi synthetic biology industrial park and related manufacturing capacity build-out.
Business Operations and Segment Role
Cathay Biotech’s business is concentrated in the biomaterials segment of the plastics industry, especially materials that feed into polyamide production. Rather than acting as a conventional plastics processor, the company operates upstream in biopolymer monomers and engineered polymer materials.
Its core industrial role can be summarized as follows:
- R&D and process development in synthetic biology and biomanufacturing.
- Production of monomers such as long-chain diacids and pentanediamine.
- Production of bio-based polyamides and related materials.
- Integration into downstream polymer supply chains for fibers, engineering plastics, and specialty applications.
The Taiyuan project is notable because it appears to be designed as a large-scale industrial anchor for the group’s biopolymer expansion, including upstream feedstock processing and downstream polyamide manufacturing.
Products and Technologies
Cathay Biotech’s product portfolio is centered on bio-based monomers and bio-based polyamides. The company states that it uses synthetic biology and bio-manufacturing technology to produce new materials at industrial scale.
Representative product and technology areas include:
- Long-chain diacids for polyamide synthesis.
- Pentamethylene diamine (PDA), also referred to in the company’s communications as a key monomer for bio-based polyamides.
- PA5X polyamides, produced at the Wusu site from 2021 onward.
- Bio-based polyamides for industrial and consumer applications.
Technically, this positioning places the company in the transition from petrochemical monomers toward renewable or fermentation-derived intermediates. In practical industrial terms, that means the company is competing not only on material performance, but also on process efficiency, scale-up capability, and integration into existing polyamide processing routes.
Applications and End Markets
According to company statements, Cathay Biotech’s bio-based materials are used in a range of end markets, including:
- Textiles
- Automobiles
- Electronic appliances
- Consumer goods
- Pharmaceuticals
- Perfumes
These applications are consistent with the properties associated with advanced polyamides, which are valued for mechanical strength, chemical resistance, thermal performance, and processing versatility. The company’s emphasis on monomers and polyamides suggests a focus on both commodity-like volume uses and specialty performance applications.
Global Presence and Market Position
Cathay Biotech presents itself as a company with growing industrial scale and international customer reach, while the Taiyuan project is part of a broader China-based manufacturing network. The company states that its headquarters and R&D center are in Shanghai, with manufacturing sites in Jinxiang and Wusu and a Taiyuan site under construction.
The Chinaplas exhibitor listing identifies 10 product categories, 11 applications, and repeated participation since 2016, indicating active presence in the plastics trade-exhibition ecosystem. The same listing also classifies the company as a “Shining Niche” firm and as a Chinese specialized and sophisticated enterprise in the plastics supplier context.
From a market-position standpoint, Cathay’s significance lies in its attempt to industrialize bio-based polyamide supply chains at scale, a segment that remains strategically important as manufacturers seek lower-carbon feedstocks and more diversified material sources.
Sustainability and Environmental Initiatives
Cathay Biotech’s materials strategy is aligned with the broader industry move toward bio-based and potentially lower-fossil-input polymers. The company’s use of synthetic biology and bio-manufacturing is presented as a way to produce industrial materials through biological processes rather than wholly petrochemical routes.
Relevant sustainability dimensions include:
- Renewable or bio-based feedstocks in monomer and polymer production.
- Industrial biotechnology as an alternative production pathway for selected polymer intermediates.
- Potential support for material decarbonization in downstream plastics and fiber value chains, depending on feedstock sourcing and life-cycle performance.
At the same time, the environmental profile of bio-based materials depends on the full production chain, including agricultural inputs, energy use, and plant-scale process efficiency. Public sources reviewed here do not provide enough detail to quantify the company’s life-cycle impacts, so any assessment of environmental benefit should be treated as conditional rather than absolute.
Financial Performance and Economic Impact
The available financial data in the search results relate to the listed parent company, Cathay Biotech, rather than the Taiyuan subsidiary itself. The STAR Market snapshot reports 2020 operating revenue of 1,497.19 million and net income of 457.67 million, along with R&D expenditure equal to 5.63% of operating revenue.
Those figures indicate a business model with meaningful industrial revenue and a notable commitment to research and development. The company’s expansion in Shanxi also suggests local economic importance through manufacturing investment, employment, and supply-chain development.
Leadership and Corporate Governance
Public filings identify the listed parent company as Shanghai Cathay Biotech Inc., with headquarters and R&D in Shanghai and production sites in several Chinese locations. The Taiyuan entity appears in corporate records as a wholly owned or controlled project company associated with the wider group structure.
For the Taiyuan biomaterials platform specifically, public database entries identify a legal representative and incorporation in 2020, with registered capital reported in Chinese business databases as RMB 4.6 billion. However, detailed governance information for the subsidiary is limited in the sources reviewed here.
Innovations and Future Outlook
Cathay Biotech’s future prospects appear closely tied to three factors: scale-up execution, downstream adoption of bio-based polyamides, and continued process innovation in synthetic biology. The Taiyuan site is especially important because it is intended to expand capacity substantially, including the group’s long-chain diacid and pentanediamine platform.
Likely strategic priorities include:
- Completing and ramping the Taiyuan production base.
- Increasing the scale and efficiency of bio-based monomer production.
- Broadening downstream adoption across textiles, automotive, electrical and electronic, and other specialty applications.
- Strengthening the company’s position in the competitive transition toward bio-based engineering plastics.
Summary
CATHAY (TAIYUAN) BIOMATERIAL CO., LTD. is best understood as part of the Cathay Biotech industrial platform, positioned in the upstream bio-based materials segment of the plastics industry. Its significance lies in the planned and ongoing build-out of large-scale manufacturing for polyamide intermediates and bio-based polyamides, supported by synthetic biology and biomanufacturing capabilities.
References
- •
CPS+ eMarketplace. (n.d.). CATHAY (TAIYUAN) BIOMATERIAL CO., LTD.CATHAY (TAIYUAN) BIOMATERIAL CO., LTD.. CPS+ eMarketplace. https://www.chinaplasonline.com/eMarketplace/ExhibitorInfo?CompId=1001331Link